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J.A. Caprini,1,2* S. Goldshteyn,1,2 C.J. Glase1 and K. Hathaway11Department of Surgery, Evanston Northwestern Healthcare, Evanston, and 2Northwestern University
Feinberg School of Medicine, Chicago, IL, USABackground. Routine thrombophilia testing is controversial because of the low yield of positive tests, costs involved, and
debate about the clinical usefulness of the data obtained from testing. Laboratory investigations are rarely done for those with
superficial venous thrombosis (SVT) or isolated calf vein thrombosis (CVT) which are often not treated with anticoagulants.
Objective. To identify the incidence of markers of thrombophilia in patients with deep vein thrombosis (DVT), SVT, isolated
CVT or a history of thrombosis in a referral practice.
Methods. One hundred and sixty-six patients were referred to our thrombosis unit for consultation, including patients with
SVT, DVT, and preoperative patients with a previous history of SVT or DVT. Patients underwent thrombophilia screening
and patients with a diagnosis of SVT or DVT were confirmed by bilateral duplex ultrasonography of all lower limb veins.
Thrombophilia testing included factor V Leiden (FVL), prothrombin 20210A mutation (P2), methylene tetrahydrofolate
reductase deficiency (MTHFR), fasting serum homocysteine (HC), lupus anticoagulant (LA), anticardiolipin antibodies
(ACA), antithrombin deficiency (AT), protein S deficiency (PS), and protein C deficiency (PC).
Results. The incidence of any significant abnormality in patients with DVTwas 27/44 (61%; 95% Confidence interval [CI],
47–76%) and 10 of these patients were positive for FVL (23%; 95% CI, 10–35%). Twelve patients with isolated CVT were
seen and five had at least one abnormality (42%; 95% CI, 14–70%) including one with FVL (8%; 95% CI, 0–24%). Thirty-
nine patients with isolated SVT were seen including 14 with at least one abnormality (36%; 95% CI, 21–51%) and five of
these patients with SVT had FVL (13%; 95% CI, 2–23%). Nine patients with recurrent DVT were seen and five of these had
at least one abnormal test (56%; 95% CI, 23–88%). Finally, 18 of the 166 patients had more than one abnormality (11%;
95% CI, 6–16%).
Conclusion. The presence of one or more markers of thrombophilia was significantly higher in this patient population
compared to reports from other centres. This study identified 18/166 (10.8%; 95% CI, 6–16%) with more than one defect
where life-long anticoagulation might be considered. The results in this subset of patients as well as the serious defects found
in some patients with provoked DVT, isolated CVT or isolated SVT demonstrate the value of this screening program to both
these patients and their blood relatives. On the other hand, this is a small series from a referral practice where the incidence of
these defects is greater than one would expect in the general population. These studies are preliminary and it is not
recommended that all VTE patients should be screened on the basis of the current report.Keywords: Thrombophilia; Genetic markers; Venous thrombosis; Calf vein thrombosis; Superficial venous thrombosis.The introduction of the term thrombophilia by
Egeberg in 1975 followed his description of a
tendency to develop deep vein thrombosis (DVT)
in a Norwegian family that was subsequently
shown to have antithrombin deficiency.1 Sub-
sequently, a number of additional defects in
patients with venous thromboembolism (VTE)
have been described.2 The overall incidence of
these disorders in the general population is low, so
routine testing is not justified. There are no clear-cutthe 16th annual meeting of the American Venous
do, Florida, February 26–29, 2004.
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VTE3,4 and even less information regarding testing of
patients with superficial venous thrombosis (SVT) or
isolated calf vein thrombosis (CVT). Zwicker5 has
reported that patients testing positive for certain
combinations of two or more defects may result in a
70–90% risk of recurrent thrombosis during their
lifetime.
We embarked on a program of routine thrombo-
philia testing in patients referred for thrombosis
management or preoperative consultation because of
a previous DVT. The aim was to determine the
incidence of thrombophilic defects in these patients
and to assess the clinical usefulness of the information
obtained from this screening.Eur J Vasc Endovasc Surg 30, 550–555 (2005)
doi:10.1016/j.ejvs.2005.05.034, available online at http://www.sciencedirect.com onved.
Thrombophilia Testing 551MethodsPatient referral and duplex scan verification
Patients referred to the primary author’s practice
included those with SVT, DVT, patients with venous
disease, or with a personal or family history of DVT
who required elective surgery and needed advice
regarding the type and extent of thrombosis prophy-
laxis. All of these patients underwent bilateral lower
limb duplex scanning and were questioned regarding
past episodes of personal VTE and family history to
uncover any thromboembolic events in blood-related
individuals. Each patient underwent a careful throm-
bosis risk assessment, including specific questions
regarding previous major surgery, cancer, prior myo-
cardial infarction, past major trauma, or other serious
medical disease. We also recorded medications, includ-
ing oral contraceptives and hormone replacement
therapy. Bilateral venous duplex ultrasonography
was done using a high-resolution machine (Ultra-
mark9-HDI, Advanced Technology Laboratories,
Bothell, WA). The patients were placed in reverse
Trendelenburg position at approximately a 10–208
angle to examine the common femoral, femoral,
profunda femoris, great and small saphenous veins.
The examination began at the level of the common
femoral vein just below the inguinal ligament. The
distal femoral, popliteal, and calf veins were examined,
when possible, in the dependent position with a leg
resting on the operator’s lap. This manoeuvre produces
dilatation of the veins and improves image quality. If
the patient was unable to sit, the leg was externally
rotated and the test performed in the supine position.
All the veins were examined in the transverse and
longitudinal views.
The abnormal examination criteria that indicated
DVTincluded: No venous Doppler signals present with
respiration or augmentation manoeuvres, vein lumen
filled with echogenic material, and inability to com-
press the vein with gentle probe pressure that was not
as a result of extra vascular causes. At least two criteria
were required for the diagnosis of DVT. Thrombi that
extended to the popliteal vein or above were con-
sidered proximal, whereas those clots that were limited
to the calf were considered distal. This technique has
previously been reported and validated.6Thrombophilia screening
Thrombophilia tests were ordered for patients based
on the risk factors associated with the development of
VTE at the time of their clinical evaluation. Specificindications for testing included patients with a personal
or family history of VTE, women with a history of
unexplained stillborns, or patients with a personal or
family history of stroke or myocardial infarction.
The three genetic mutations examined included
factor V Leiden, prothrombin 20210A, and methylene
tetrahydrofolate reductase deficiency (MTHFR). The
remaining thrombophilia markers consisted of antith-
rombin, protein C and S functional, and acquired
antiphospholipid antibodies which included lupus
anticoagulant, and fasting serum homocysteine.
The first three mutations were evaluated using a
signal amplification program known as the ‘Invader
method’ (Third Wave Technologies [Madison, WI]). All
remaining tests involved blood drawn using standard
venous phlebotomy at Glenbrook Hospital, Glenview,
IL, USA. A 2.7-mL buffered sodium citrate (9:1)
vacutainer tube was used to obtain blood for protein
S, C, and antithrombin levels. A chromogenic method
was employed for antithrombin and protein C activity
(Dade Behring [Deerfield, IL]), whereas a clotting
method determined results for protein S (Biopool)
and lupus anticoagulant (Dade Behring [Deerfield, IL]).
Homocysteine values were obtained on a specimen of
blood drawn into a 3-mL potassium EDTA (ethylene
diamine tetra-acetic acid) 5.4-mL vacutainer tube.
Normal homocysteine ranges were produced with an
adviaventaur (Bayere [Pittsburgh, PA]). Finally, blood
for anticardiolipin antibodies was drawn into a 5-mL
serum separator (SST) vacutainer tube gel and clot
activator. An enzyme immunoassay kit manufactured
by Diamedix was used to evaluate ranges. These assays
were all obtained either prior to the institution of
anticoagulation therapy or after the patients had
completed their course of anticoagulation treatment.
Table 1 shows the reference ranges for these tests and
indicates what we considered to be significant abnorm-
alities. Heterozygous MTHFR mutations were not
considered abnormal since these are present in up to
30% of normal individuals.7 We also excluded border-
line or mild elevations of anticardiolipin antibodies as
positive test results. None of these abnormalities has
been shown to be important in thrombosis manage-
ment.7,8 Table 2 shows the number of patients in each
group. The breakdown between significant and overall
findings in various patient groups is seen in Table 3.Statistical methods
SPSS version 11.5 package (Statistical Package for
Social Sciences Inc., Chicago, IL) was used for all
statistical analyses. Cross-tabulation of variables was
performed and included the frequency of eachEur J Vasc Endovasc Surg Vol 30, 11 2005
Table 1. Thrombophilia tests
Test Results Significant positive results
Factor V Leiden mutation Heterozygous, homozygous, negative, not performed Heterozygous, homozygous
Prothrombin mutation Heterozygous, homozygous, negative, not performed Heterozygous, homozygous
MTHFR mutation Heterozygous, homozygous, negative, not performed Homozygous
ACA-IgG (GPL units) !10: Negative; 10–20: Low positive; 21–80: Medium positive; O80: High
positive
O21: Positive
ACA-IgA (APL units) !12: Negative; 12–15: Borderline; O15: Positive O15: Positive
ACA-IgM (IGM units) !10: Negative; 10–20: Borderline; 21–80: Medium positive; O80: High positive O21: Positive
Homocysteine 0–13 mmol/LZnormal; O13 mmol/LZabnormal O13 mmol/LZabnormal
Lupus anticoagulant Positive, negative, not performed (ratio%1.30) Positive
Antithrombin III Normal range: 72–148% activity !72Zabnormal
Protein C functional Normal range: 66–142% activity !66Zabnormal
Protein S functional Normal range: 64–140% activity !64Zabnormal
J. A. Caprini et al.552abnormality. Along with exact proportions, 95%
confidence intervals were calculated.Results
The study included 166 patients with some form of
thrombosis or history of thrombosis who were referred
for primary or secondary VTE management over a
2-year period. This included patients referred for
evaluation before an elective surgical procedure or for
management of venous disease. Table 2 lists the
location of thrombi as well as important historical
information. A broad range of abnormal tests was seen
in the various patient groups. Some patients had more
than one thrombotic location and some individuals had
more than one defect. We defined a personal or family
history of VTE as those cases with objective evidence of
a thrombosis (i.e. duplex scan, venogram, lung scan).
The results of thrombophilia testing for these same
categories are seen in Tables 3–5. Forty-four patients
with a DVT were seen and 27/44 (61; 95% CI, 47–76%)
of these individuals had a significant abnormality.
Twelve of the DVT patients shown in Table 3 had CVT
only and five of these 12 (42%; 95% CI, 14–70%)
individuals had a positive marker for thrombophilia.
Also included in the DVT group seen in Table 3 were
nine patients with recurrent DVT and five ofTable 2. Number of patients
Number of patients
All DVT* 44/166 (26.5%)
CVT only† 12/166 (7.2%)
SVT only 39/166 (23.5%)
Recurrent DVT 9/166 (5.4%)
Hx DVT 73/166 (44.0%)
Hx PE 32/166 (19.3%)
Family Hx DVT 54/166 (32.5%)
Any DVT/SVT withO1 abnormality 18/166 (10.8%)
* Proximal DVT with or without calf involvement.
† Calf only DVT excludes patients with proximal clots.
Eur J Vasc Endovasc Surg Vol 30, 11 2005these (56%; 95% CI, 23–89%) had a significant
abnormality.
Superficial thrombosis not associated with DVT or
PE was seen in 39 patients in the study, including 14
individuals with a positive marker as seen in Table 3
(36%; 95% CI, 21–51%). Five of these patients with a
positive marker had a factor V Leiden defect including
two homozygous and three heterozygous gene
mutations. Finally, we found 18 patients with more
than one defect and 14 of these individuals had a past
history of thrombosis (78%; 95% CI, 59–97%). Other
categories of patients with two defects included: Acute
DVT 9/18 (50%; CI 95%, 27–73%), history of PE 5/18
(27%; 95% CI, 6–48%), 4/18 (22%; 95% CI, 3–41%)
patients each had recurrent DVT or a family history
of DVT, and 2/18 patients had SVT only (11%; 95% CI,
0–25%).
Table 5 shows the incidence of thrombophilic
markers in patients with provoked vs. spontaneous
clots. As expected, a greater percentage of spon-
taneous clots were associated with positive markers.
It is interesting to note the relatively high percentage of
positive markers in those with provoked clots.Discussion
It is important for the reader to understand that we
screened everyone with DVT since they were referred
to us for assessment of the cause of their DVT. We
even screened those with clear causes for their DVT
since some of them proved to have a thrombophilia
and this we felt added to the value of our assessment.Provoked thrombosis
An interesting finding from our study is the percen-
tage of patients with so-called ‘provoked’ thrombosis
who were found to have a thrombophilic defect.
‘Provoked events’ in this study were defined as those
Table 3. Genetic mutations
Reason for test Significant
abnormality
Factor V
Leiden
Prothrombin
20210A
MTHFR* Antithrombin Protein C Protein S Homocysteine
All DVT 27/44 (61%) 10/44 (23%) 6/44 (14%) 6/44 (14%) 1/44 (2%) 3/44 (7%) 2/44 (5%) 4/44 (9%)
CVT only 5/12 (42%) 1/12 (8%) 0/12 (0%) 0/12 (0%) 0/12 (0%) 0/12 (0%) 0/12 (0%) 2/12 (17%)
SVT only 14/39 (36%) 5/39 (13%) 3/39 (8%) 1/39 (3%) 0/39 (0%) 1/39 (3%) 1/39 (3%) 4/39 (10%)
Recurrent DVT 5/9 (56%) 3/9 (33%) 1/9 (11%) 1/9 (11%) 0/9 (0%) 1/9 (11%) 3/9 (33%) 1/9 (11%)
History of DVT 41/73 (56%) 17/73 (23%) 9/73 (12%) 3/73 (4%) 1/73 (1%) 5/73 (7%) 1/73 (1%) 10/73 (14%)
History of PE 16/32 (50%) 3/32 (9%) 4/32 (13%) 2/32 (6%) 0/32 (0%) 1/32 (3%) 1/32 (3%) 5/32 (16%)
Family history
of DVT
23/54 (43%) 11/54 (20%) 6/54 (11%) 2/54 (4%) 0/54 (0%) 1/54 (2%) 0/54 (0%) 5/54 (9%)
Any DVT/SVT
withO1
18/18
(100%)
7/18 (39%) 6/18 (33%) 5/18 (28%) 1/18 (6%) 3/18 (17%) 5/18 (28%) 7/18 (39%)
* Homozygous only.
Thrombophilia Testing 553where venous thrombosis resulted from surgery, leg
injuries, prolonged travel, oral contraceptives or
hormone replacement. None of these provoked cases
was due to intravenous catheters or post-partum, and
the numbers are too small to break down according to
type of event. Eleven of the 44 DVT patients (25%; 95%
CI, 12–38%) were judged to have a provoked event.
Surprisingly, five of the 11 provoked DVT patients
(46%; 95% CI, 16–75%) were found to have a
thrombophilia. It should be noted that this is simply
an observation to alert the clinician that even though
the event is provoked, a thrombophilic defect may still
be present. It is for the reader to decide which of these
patients needs to be screened. A spontaneous DVT was
seen in 33/44 (75%; 95% CI, 62–87%) of the patients
and 22/33 (67%; 95% CI, 51–83%) of these had a
positive marker for thrombophilia, as seen in Table 5.
Although the sample size is small and the confidence
interval wide, individual patient care was potentially
improved by finding these defects. While many phys-
icians do not recommend testing those with known
causes of thrombosis (provoked), if a serious defect were
found, prolonged anticoagulation may be necessary.Isolated SVT
At least one abnormality was found in 14/39 (36%; 95%
CI, 21–51%) patients with isolated SVTand three of these
patients were considered to have a provoked event. The
most important defects identified included one patientTable 4. Antiphospholipid antibodies
Reason for test IgG Ig
All DVT 0/44 (0%) 0
CVT only 0/12 (0%) 0
SVT only 0/39 (0%) 1
Recurrent DVT 0/9 (0%) 0
History of DVT 0/73 (0%) 1
History of PE 0/32 (0%) 0
Family history of DVT 0/54 (0%) 0
Any DVT/SVT withO1 abnormality 0/18 (0%) 1each with protein C, protein S, antiphospholipid
antibodies, and lupus anticoagulant. Two of these
patients also had homozygous factor V Leiden. Most
investigators treat these patients with life-long antic-
oagulation.9,10 To our knowledge, testing for markers of
thrombophilia in those with provoked SVT has not been
done and may represent one tiny contribution that is
unique to this paper. We know that women of child-
bearing age found to have positive markers would be at
increased risk for developing thrombosis during sub-
sequent pregnancies. This is just an observation,
however, and the authors are not suggesting that every
female with SVT be subjected to screening.
An interesting perspective is provided by the
recently published long-term epidemiologic studies
from Heit at the Mayo Clinic that showed a startling
25% of patients with acute PE presented as sudden
death. Recurrent thromboembolism over 16,430 per-
son-years of follow-up resulted in a 7-day case fatality
of 16.7%. The authors concluded that routine screen-
ing of patients with a first episode of thrombosis, and
long-term treatment of those with positive markers,
could have lowered this death rate.11
In our study, the frequency of positive markers is
higher than those reported in other studies concerning
patients with VTE.7,12 However, our data concern a
relatively small patient group compared to some other
publications. The reader should be careful to note that
the management of the patient is not necessarily
influenced by the presence of factor V Leiden in theA IgM Lupus anticoagulant
/44 (0%) 0/44 (0%) 4/44 (9%)
/12 (0%) 0/12 (0%) 2/12 (17%)
/39 (2.6%) 0/39 (0%) 1/39 (3%)
/9 (0%) 0/9 (0%) 0/9 (0%)
/73 (1%) 3/73 (4%) 3/73 (4%)
/32 (0%) 2/32 (6%) 3/32 (9%)
/54 (0%) 1/54 (2%) 2/54 (4%)
/18 (6%) 1/18 (6%) 3/18 (17%)
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Table 5. Provoked vs. idiopathic events
Reason for test Total patients Positive markers Patients with a provoked event Patients with an idiopathic event
No marker Positive marker No marker Positive marker
DVT 44 27 (11/44) 25% (5/11) 45% (33/44) 75% (22/33) 67%
Calf only 12 5 (5/12) 42% (1/5) 20% (7/12) 58% (4/7) 57%
SVT only 39 14 (11/39) 28% (3/11) 27% (28/39) 72% (11/28) 39%
J. A. Caprini et al.554heterozygous form of this gene mutation. We found
the incidence of factor V Leiden in our study (22%) to
be in agreement with other reports.13 Investigation of
selected patient groups by Eichinger revealed a 20–
50% incidence of FVL in patients with primary or
recurrent VTE, with the highest figures being seen in
women with a history of thrombosis during pregnancy
or the puerperium.14 Clark has suggested that
selective screening of pregnant patients with a history
of thrombosis or pregnancy-related complications
may identify the factor V Leiden gene in 20–40% of
patients.15 Factor V Leiden has been found to be the
most common defect and is seen in approximately 20%
of patients developing venous thrombosis. There is a
great deal of controversy regarding the significance of
factor V Leiden increasing the risk of recurrent venous
thrombosis compared to patients without the gene.
This controversy has led some investigators to omit
screening for FVL since studies have shown that a
positive test for this will not change the length of
anticoagulation in persons with a first DVT.2Calf vein thrombosis
Two additional findings in this study are the incidence
and type of thrombophilias seen in patients with CVT
alone. Treatment of patients with isolated CVT or SVT is
not routinely done in some centres despite the fact that
significant morbidity and mortality can occur in some of
these cases.16 In addition, most physicians do not
measure thrombophilia markers in such patients.
While there were only 12 patients in this group, two
individuals had a lupus anticoagulant, which many
physicians feel merits life-long anticoagulation.10
Abnormal homocysteine levels were seen in two other
patients with calf thrombosis only. Many experts would
advocate prophylactic vitamins to help prevent stroke,
myocardial infarction, and arterial and venous throm-
bosis in such patients, although randomised controlled
clinical trials have not been done to prove the value of
this prophylaxis.17 One patient in the calf thrombosis
group was heterozygous for factor V Leiden, which
would not change the approach to treatment for the calf
vein thrombosis but may have other implications for
blood relatives, especially those who are contemplating
birth control pills or hormone replacement therapy.18Eur J Vasc Endovasc Surg Vol 30, 11 2005The value of knowing about positive markers such
as factor V Leiden, prothrombin 20210A and MTHFR
in this group is less evident. However, some of these
patients were of child-bearing age and developed SVT
during or after a previous pregnancy. If these women
were to become pregnant again, the incidence of DVT
without prophylaxis during pregnancy could be
higher than in the general pregnant population. We
feel that thrombosis prophylaxis with anticoagulants
during and following such a pregnancy may be of
value. Similarly, if patients who develop an SVT
during pregnancy subsequently wish to use oral
contraceptives to space out their pregnancies but do
not know they are carrying one of these defects, they
may have a much higher incidence of VTE compared
to patients without a positive thrombophilia marker
taking oral contraceptives.Multiple thrombophilic defects
We found 18 patients in our population with more
than one significant thrombophilia defect, including
two patients with SVT. The incidence of recurrent
venous thrombosis in patients with more than one
defect has been estimated to be 70–90% according to
Zwicker.5 In our opinion, the potential high thrombo-
tic risk in these individuals would have been missed
were it not our policy to test those with SVT for
thrombophilias. In both of our patients, these events
occurred during pregnancy and we treated both
patients with anticoagulants. We also cautioned them
not to take oral contraceptives since the incidence of
serious VTE events is much higher than in those
without defects of thrombophilia.2 Westrich has
reported that the presence of multiple genetic defects
was more frequent in patients developing postopera-
tive pulmonary emboli compared to those not
developing postoperative thrombosis.19 He suggested
that more aggressive thrombosis prophylaxis was
indicated in these individuals.Family history of thrombosis
Also of great importance was the finding that 22% of
patients with a family history of VTE had two defects.
Thrombophilia Testing 555This is the same rate we found in patients with recurrent
venous thrombosis where one would expect to find a
marker of thrombophilia. This fact highlights the value
of eliciting a careful family history in all patients,
particularly those who require surgery. The most
frequent observation we have made during hospital
consultations on patients with a postoperative throm-
bosis is that no one asked them about their family history
of VTE. These patients require careful attention since
they are candidates for life-long anticoagulation and the
most intense perioperative thrombosis prophylaxis
should additional surgery be necessary.General remarks
The fact that 61% of DVT patients had at least one
abnormality may reflect the nature of our referral
practice. We would be the first to caution about routine
testing based on these data because the sample size in
this study is very small. The wide confidence intervals
of most of these findings emphasize the pilot nature of
our study. On the other hand, we discovered a number
of patients with potentially serious defects. It should
be noted that this is a referral practice where most of
the patients seen have a personal or family history of
VTE. The incidence of thrombophilic defects in this
group is much higher than in the general population.
The data set is too small to allow a multivariate model
to predict the risk of recurrent thrombosis.
We acknowledge the important work of Baglin, who
pointed out that in unselected patients with a first
episode of venous thrombosis, the presence of
hereditary thrombophilia did not predict a recurrent
event within 2 years of stopping anticoagulation. We
do not have enough numbers or data to make any
statement except to agree with his conclusions.20 As
previously mentioned, the small size of this study
which is from a referral practice where the incidence of
thrombophilia is higher than in the average clinical
practice should caution the reader that it is premature
to advocate routine screening of all DVT patients.
However, we feel that this study does point out that
even those with SVT or DVT limited to the calf may
harbour a thrombophilic defect.
The nature of our data collection and the small size
of this series preclude making any statement regard-
ing the cost effectiveness of this approach. Again, a
larger study needs to be done before such an analysis
would be appropriate. We hope others will expand on
these data and provide larger studies to validate or
refute our preliminary results.References
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